Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04334174
Title	Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (BRENTICON-T)
Acronym	BRENTICON-T
Recruitment	Withdrawn
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	University of Kansas Medical Center
Indications	adult T-cell leukemia/lymphoma peripheral T-cell lymphoma angioimmunoblastic T-cell lymphoma hepatosplenic T-cell lymphoma anaplastic large cell lymphoma
Therapies	Brentuximab vedotin
Age Groups:	adult \| senior
Covered Countries	USA